Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study

Ophthalmology

Volumn 119, Issue 5, 2012, Pages 1001-1010

  Kaiser, Peter K ^a   Boyer, David S ^b   Cruess, Alan F ^c   Slakter, Jason S ^d   Pilz, Stefan ^e   Weisberger, Annemarie ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; BLEPHARITIS; CHOROID DISEASE; COMPARATIVE EFFECTIVENESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; HUMAN; HYPEREMIA; LACRIMATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULOPATHY; SIDE EFFECT; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84860450956     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.02.003     Document Type: Article

References (28)

1. P.K. Kaiser Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration Curr Med Res Opin 23 2007 477 487 (Pubitemid 46463889)
2. L.P. Aiello, J.M. Northrup, B.A. Keyt Hypoxic regulation of vascular endothelial growth factor in retinal cells Arch Ophthalmol 113 1995 1538 1544
3. D.A. Antonetti, A.J. Barber, L.A. Hollinger Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors J Biol Chem 274 1999 23463 23467
4. N.S. Harhaj, D.A. Antonetti Regulation of tight junctions and loss of barrier function in pathophysiology Int J Biochem Cell Biol 36 2004 1206 1237 (Pubitemid 38519069)
5. T. Ishibashi Cell biology of intraocular vascular diseases [in Japanese] Nihon Ganka Gakkai Zasshi 103 1999 923 947
6. U. Schmidt-Erfurth, T. Hasan Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration Surv Ophthalmol 45 2000 195 214
7. Verteporfin In Photodynamic Therapy Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2 Am J Ophthalmol 131 2001 541 560
8. Verteporfin in Photodynamic Therapy (VIP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3 Ophthalmology 110 2003 667 673
9. P.K. Kaiser Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8 Graefes Arch Clin Exp Ophthalmol 244 2006 1132 1142 (Pubitemid 44269592)
10. U. Schmidt-Erfurth, U. Schlotzer-Schrehard, C. Cursiefen Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest Ophthalmol Vis Sci 44 2003 4473 4480 (Pubitemid 37186285)
11. T. Busch Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment Retina 29 suppl 2009 S36 S38
12. L. Spielberg, A. Leys Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years Graefes Arch Clin Exp Ophthalmol 248 2010 943 956
13. Visudyne in Minimally Classic Choroidal Neovascularization Study Group Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial Arch Ophthalmol 123 2005 448 457
14. M.J. Potter, C.C. Claudio, S.M. Szabo A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study Br J Ophthalmol 94 2010 174 179
15. C. Costagliola, M.R. Romano, M. Rinaldi Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration Br J Ophthalmol 94 2010 180 184
16. N. Ferrara, L. Damico, N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870 (Pubitemid 44547437)
17. J. Lowe, J. Araujo, J. Yang Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp Eye Res 85 2007 425 430 (Pubitemid 47542265)
18. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study Ophthalmology 116 2009 57 65
19. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
20. F.G. Holz, W. Amoaku, J. Donate SUSTAIN Study Group Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study Ophthalmology 118 2011 663 671
21. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
22. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study Ophthalmology 118 2011 831 839
23. A.N. Antoszyk, L. Tuomi, C.Y. Chung, A. Singh FOCUS Study Group Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results Am J Ophthalmol 145 2008 862 874
24. U. Schmidt-Erfurth, S. Wolf PROTECT Study Group Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration Br J Ophthalmol 92 2008 1628 1635
25. M. Larsen, U. Schmidt-Erfurth, P. Lanzetta et al. Verteporfin plus Ranibizumab for choroidal Neovascularization in age-related macular degeneration: twelve-month MONT BLANC, study results Ophthalmology 119 2012 992 1001
26. B. Gupta, T. Adewoyin, S.K. Patel, S. Sivaprasad Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration Br J Ophthalmol 95 2011 386 390
27. D.S. Boyer, A.N. Antoszyk, C.C. Awh MARINA Study Group Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 246 252 (Pubitemid 46172497)
28. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 Am J Ophthalmol 136 2003 407 418